ETCare: Safety and Preliminary Efficacy Trial

Completed · Early Phase 1

Conditions studied: Respiratory Distress Syndrome, Newborn

In brief

When babies are sick, or are born prematurely, they sometimes need an endotracheal (ET) tube to assist their breathing and/or a nasal canula. The investigators must periodically irrigate the ET tube to prevent them from being plugged up by secretions. The investigators also, due to the drying effects of nasal canula, periodically moisten the nasal passages of babies. Presently 0.9% saline is the solution being used for moistening of the ET tube, nose, as well as oral cares will infant is not eating. However, scientists have recently learned that saline can destroy the body's natural antibacterial properties in the windpipe, nose, and mouth. The investigators have developed a new solution to be used in place of saline for endotracheal (ET), nasal, and oral cares. The investigators' new solution is patterned after the natural fluid in the windpipe, nose, and mouth. Study Hypothesis: 1. Patients who receive ETCare will have no increase in adverse events related to its administration, compared with 0.9% saline. 2. Patients who receive ETCare will have a lower proportion of tracheal aspirates where pathogens are reported. 3. Patients who receive ETCare will have a lower proportion of tracheal aspirates where leukocytes are reported. 4. Patients who receive ETCare will have fewer (risk-adjusted) days of supplemental oxygen.

Key facts

Study ID
NCT01688440
Run by
Intermountain Health Care, Inc.
People needed
10
Starts
2005-06-01
Expected to finish
2005-09-01
Last updated by the study team
2012-09-19

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.